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The current therapeutic strategy for patients with lung cancer is based on a combinationof the histologic type, tumor, node, metastasis (TNM) stage, and physical status of the
patients, and therefore, these are categories for which accurate information must be
obtained before the initiation of treatment. In the course of assessment of patients with
non-small cell lung cancer, the additional tumor nodules (ATNs) are often found in
addition to the main tumor nodule, either in the same lobe or in the contralateral lobe/side.
The existence of ATNs crucially influence on the determination of the TNM stage and the
treatment (Figure 1). In the revised new TNM classification for lung cancer (UICC-7),
which has already been in effect since January 2010, the inclusion of ATN is one of the
important revisions.1 In the event that ATNs are found in the same lobe as the main tumor
nodule, the tumor is categorized as T3 (formerly T4). If the ATN is in a different lobe but
the same side, it is categorized as T4 (formerly M1). If present on the contralateral side,
it is categorized as M1a (formerly M1). The prognostic appropriateness of such catego-
rization needs to be evaluated further; however, these categories are based on the
assumption that these ATNs are metastases from the original main lung cancer. There are
other possibilities that arise in the course of daily practice.
In fact, when multiple synchronous lung tumors are present, it is quite difficult to
differentiate multicentric lung cancers from a single lung cancer with either intrapulmonary
metastases or pulmonary metastases from a primary cancer in a different organ. The possibility
that the additional nodules are inflammatory granulomas, despite the malignant status of the
primary nodule, must be also addressed. There are no specific clinical or radiologic features
that can reliably differentiate the multiple primary lung cancers (MPLCs) and intrapulmonary
metastases. There have been many attempts to define MPLCs in terms of clinical presentation,
histopathology, and more recently, the molecular/genetic profile. In 1975, Martini and
Melamed2 proposed the criteria for the diagnosis of MPLC. It has been defined as occurring
when (1) the histologies are different, and (2) the histologies are the same but the following
criteria are met: the origin is from a carcinoma in situ, with no lymph node involvement in the
common lymphatic pathways, and no extrathoracic metastasis. Because of the easy applica-
bility of these criteria, they have entered standard use by clinicians and pathologists ever since
the original publication in mid-1970s.
Subsequently, modified criteria have been proposed with the addition of new factors
such as the histologic subtype and molecular/genetic profiles. Antakli et al.3 modified the
original Martini and Melamed criteria by adding premalignant lesions and DNA ploidy.
With regard to DNA ploidy, a different ploidy pattern was suggested as an indicator of
different tumor cell origin. However, it must be addressed that a different DNA ploidy
pattern does not exclude the possibility of the same tumor cell origin, because of the
heterogeneity of the DNA ploidy within the same tumor and also the change in the ploidy
pattern that comes with tumor progression. In 2007, the American College of Chest
Physicians (ACCP guidelines prepared by Shen et al.4) presented a new classification in
which even for the same histologies, MPLC could be identified if these tumors possessed
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different molecular/genetic characteristics. In the reported
literature, the mutation of p535 and epidermal growth factor
receptor/KRAS6 has been used as a marker to demonstrate the
clonal relationships among separate tumors. Certain discrep-
ancies between the results obtained by clinicopathological
criteria and by genetic/molecular criteria have also been
reported.
In a report by Tanvetyanon et al.7 entitled “Relationship
between tumor size and survival among patients with resec-
tion of multiple synchronous lung cancers,” the authors
studied the prognostic impact of the size of the main tumor in
patients who had undergone surgical resection for at least two
simultaneous MPLCs in two or more lobes. They used both
the size of the largest tumor and the sum of the tumor sizes
and found tumor size to be an independent predictor of
survival by multivariate analysis. They also showed that the
size of the largest tumor performs slightly better that the sum
of the tumor sizes in survival prediction. The results of this
article suggest a means of dealing with patients afflicted with
MPLCs based on tumor size. When tumor size determination
is made before treatment, it allows for a rough prognosis after
the resection, and thus it may impact the treatment of choice.
However, there is still no definitive method of identi-
fying MPLCs before treatment. It is only very recently that
the genetic/molecular profiles have begun to be incorporated
into the diagnosis of MPLCs. Moreover, even if a method of
gene/molecular profiling with a small specimen is estab-
lished, the issue of tissue sampling from the smaller ATNs
remains. Most ATNs are generally less than 1 cm in diameter
in the lung parenchyma, and sampling from such multiple
tiny locations in the lung is intrinsically difficult, even with
sophisticated computed tomography-guided techniques.
In terms of the current outstanding issues facing
MPLCs, we need to make progress both in establishing the
definitive diagnostic method and a safe, reliable tissue sam-
pling technique from small lung nodules.
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FIGURE 1. Tumor, node, metastasis (TNM) stage based on
the UICC-7 of a tumor with additional tumor nodules
(ATNs) in the contralateral side (A) and multiple primary
lung cancers (MPLCs) in both sides of the lung (B). In the
case of a tumor with ATN in the contralateral side of the
lung, the TNM stage is IVa. In case of MPLC, the TNM stage
is determined by the highest stage of all lesions (stage Ib).
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